Lang M, et al. - Long term experience with everolimus, an mTOR-inhibitor, suggests its promising therapeutic benefits for patients with thymic neuroendocrine neoplasia (NEN) at least when given in second line therapy.

• Four patients (mean age 46 years, range 37-55) with progressing thymic NEN were included.

• Patients were given everolimus 10 mg/d after failure of at least one previous medical therapy.

• For a mean of 20.8 months, the disease remained stable.

• A better outcome was observed in relation to a low Ki-67 index.

• Stable disease for the longest was achieved with everolimus in 3 out of 4 patients, vs the other non surgical therapies used.

• No severe side effects occurred.